苏州泽璟生物制药股份有限公司关于自愿披露盐酸吉卡昔替尼片纳入2025年国家医保药品目录的公告

Core Viewpoint - The inclusion of JAK inhibitor, Jika Xitini (盐酸吉卡昔替尼片), in the 2025 National Medical Insurance Drug List is expected to positively impact the sales and long-term development of Suzhou Zejing Biopharmaceutical Co., Ltd. [2][5] Group 1: Drug Information - Jika Xitini (盐酸吉卡昔替尼片), marketed as Zeppping, is a novel JAK inhibitor and the first domestic innovative drug approved for treating myelofibrosis [3] - The drug works by inhibiting the activity of Janus kinases (JAK1, JAK2, JAK3, and TYK2), blocking the JAK-STAT signaling pathway to reduce inflammation and splenomegaly [3] - It has been recommended as a first-line treatment for myelofibrosis-related anemia in the 2024 CSCO guidelines [3] Group 2: Clinical Development - The NDA application for Jika Xitini for treating severe alopecia areata has been accepted by the National Medical Products Administration [4] - Phase III clinical trials for treating active ankylosing spondylitis have met primary efficacy endpoints [4] - Ongoing clinical trials are being conducted for treating moderate to severe atopic dermatitis and other autoimmune diseases [4] Group 3: Impact on Company - The inclusion in the National Medical Insurance Drug List reflects the recognition of the drug's clinical value and innovation by the National Healthcare Security Administration [5] - This development is expected to enhance the drug's affordability and accessibility for patients, promoting market expansion and increasing sales scale [5] - The company aims to collaborate closely with relevant parties to implement the insurance policy effectively [5]